EQRx and Equivalars: A new biotech with a potentially radical business model

Founded in 2019, EQRx has closed 2 massive rounds in under 13 months. It first raised a Series-A round of USD200m in Jan’20 as part of its launch. Then in Jan’21, it has again shaken up the pharma world with a USD500m Series-B EQRx is targeting Equivalar medicines EQRx’ stated…

Read More

USD 6.3B of VC/PE investment in lifescience firms in Jan’21

We recorded 114 venture capital / private equity (VC/PE) transactions pertaining to the global life sciences sector for January 2021, aggregating to a sum of USD 6.275B. USA recorded 64 transactions for with total investment of USD 4B. China reported investment of USD 1B over 15 VC/PE transactions. India saw…

Read More

USD 4.7B of VC/PE investment seen in Lifesciences spaces in November 2020

We recorded 81 VC/PE transactions pertaining to the global life sciences sector for Nov 2020, aggregating to a sum of USD 4.7B. USA recorded 46 transactions for with total investment of USD 2.5B. Around 67% of investment, spread over 40 transactions, went into supporting R&D stage companies. Vaccine companies continued…

Read More